journal article·2024-01-12

Aptamer-Modified Zinc Ferrite Nanoparticles for Autophagy-Mediated Chemotherapy and MR Imaging of Ovarian Cancer

Jinli Zhu, Yi Hu, Chen Yang, Fenfen Li, Bin Yang, Rou Li, Bensheng Qiu, Yaying Li, Lin Liu

ACS Applied Nano Materials· Volume 7· Issue 1
Publisher page

Abstract

Chemotherapy resistance is a major cause of the high mortality in ovarian cancer. Therefore, there is an urgent need to develop strategies to increase the sensitivity of ovarian cancer to chemotherapeutic medicines. Here, we synthesized nucleic acid aptamer (NucA)-modified zinc ferrite nanoparticles (NAZs), to induce pro-death autophagy for enhancing the sensitivity of ovarian cancer cells to the chemotherapeutic agent─cisplatin (DDP). First, we verified that zinc ferrite nanoparticles (ZFONPs) effectively induced intact cellular autophagy in SKOV3 cells. Moreover, the use of small-molecule autophagy inhibitors markedly curtailed cell death induced by ZFONPs. Notably, we found that ZFONPs-induced pro-death autophagy was mediated by increasing zinc ion release and thereby intracellular reactive oxygen species (ROS) production. Second, we demonstrated that the modification of ZFONPs with the tumor-targeting aptamer (NucA) endowed the nanoparticles with the ability to target tumor cells. Furthermore, the induction of death-promoting autophagy by NAZs sensitized ovarian cancer cells to DDP chemotherapy. Significantly, the constructed NAZs exhibited ovarian cancer targeting capabilities, served as T 2 -weighted magnetic resonance imaging (MRI) contrast agents, and enhanced the therapeutic effect of DDP in both in vitro and in vivo experiments. Collectively, these findings present a promising and effective approach for the precise treatment and diagnosis of ovarian cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · Extracellular vesicles in disease · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical College, Guizhou University, Guiyang 550025, Guizhou, China

Department of Respiratory and Critical Care Medicine, Guizhou Provincial People’s Hospital, Guiyang 550002, Guizhou, China

NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People’s Hospital, Guiyang 550002, Guizhou, China

Department of Burns, The First Affiliated Hospital of Anhui Medical University, Hefei 230027, Anhui, China

Hefei National Laboratory for Physical Sciences at the Microscale and the Centers for Biomedical Engineering, University of Science and Technology of China, Hefei 230027, China

Central Laboratory, Guizhou Provincial People’s Hospital, Guiyang 550002, China

Department of Nuclear Medicine, Guizhou Provincial People’s Hospital, Affiliated Hospital of Guizhou University, Guiyang 550002, China

Funding

Science and Technology Foundation of Guizhou Health Commission · Guizhou Province Science and Technology Project · Doctoral Fund of Guizhou Provincial People's Hospital · Guizhou High-level Talents Innovation and Entrepreneurship Project

References (48)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1200/JCO.2022.40.16_suppl.554010.1200/JCO.2022.40.16_suppl.5540 ↗
3. 10.1136/bmj.m377310.1136/bmj.m3773 ↗
4. 10.1093/annonc/mdz10410.1093/annonc/mdz104 ↗
5. 10.1200/JCO.2022.40.16_suppl.e1754910.1200/JCO.2022.40.16_suppl.e17549 ↗
6. 10.1093/annonc/mdx44610.1093/annonc/mdx446 ↗
7. 10.1016/j.cclet.2022.10776410.1016/j.cclet.2022.107764 ↗
8. 10.1016/j.ijpharm.2020.11998610.1016/j.ijpharm.2020.119986 ↗
9. 10.1038/nrm402410.1038/nrm4024 ↗
10. 10.1038/s41556-018-0201-510.1038/s41556-018-0201-5 ↗
11. 10.1016/j.biomaterials.2021.12089110.1016/j.biomaterials.2021.120891 ↗
12. 10.1016/j.biomaterials.2019.11924810.1016/j.biomaterials.2019.119248 ↗
13. 10.1002/advs.20200350410.1002/advs.202003504 ↗
14. 10.7150/thno.4041410.7150/thno.40414 ↗
15. 10.1039/C8NR08442D10.1039/C8NR08442D ↗
16. 10.2147/IJN.S19367610.2147/IJN.S193676 ↗
17. 10.1016/j.biomaterials.2015.11.02910.1016/j.biomaterials.2015.11.029 ↗
18. 10.1002/advs.20190332310.1002/advs.201903323 ↗
19. 10.1021/acsami.2c0055210.1021/acsami.2c00552 ↗
20. 10.1038/s41467-018-04255-z10.1038/s41467-018-04255-z ↗
21. 10.1021/acsanm.3c0205910.1021/acsanm.3c02059 ↗
22. 10.1021/acsanm.3c0006710.1021/acsanm.3c00067 ↗
23. 10.1016/j.molmed.2020.05.00210.1016/j.molmed.2020.05.002 ↗
24. 10.1007/s10637-013-0045-610.1007/s10637-013-0045-6 ↗
25. 10.1021/acsami.0c1828210.1021/acsami.0c18282 ↗
26. 10.1021/acsami.3c0196710.1021/acsami.3c01967 ↗
27. 10.1021/acsami.2c1619910.1021/acsami.2c16199 ↗
28. 10.1016/j.ijbiomac.2019.11.11810.1016/j.ijbiomac.2019.11.118 ↗
29. 10.3390/nano1110262810.3390/nano11102628 ↗
30. 10.1039/D2TB02186B10.1039/D2TB02186B ↗
31. 10.1016/j.msec.2014.10.06210.1016/j.msec.2014.10.062 ↗
32. 10.1002/adfm.20200199410.1002/adfm.202001994 ↗
33. 10.1021/acsami.8b0908610.1021/acsami.8b09086 ↗
34. 10.1016/j.jmst.2020.11.05810.1016/j.jmst.2020.11.058 ↗
35. 10.1016/j.aca.2020.10.02410.1016/j.aca.2020.10.024 ↗
36. 10.1042/BCJ2021031410.1042/BCJ20210314 ↗
37. 10.1080/15548627.2022.211751510.1080/15548627.2022.2117515 ↗
38. 10.1016/j.nantod.2023.10179810.1016/j.nantod.2023.101798 ↗
39. 10.1038/s41419-020-03242-x10.1038/s41419-020-03242-x ↗
40. 10.1016/j.semcancer.2021.06.02010.1016/j.semcancer.2021.06.020 ↗
41. 10.1007/s10311-020-01033-610.1007/s10311-020-01033-6 ↗
42. 10.1016/j.scitotenv.2022.15362910.1016/j.scitotenv.2022.153629 ↗
43. 10.3109/17435390.2014.97470910.3109/17435390.2014.974709 ↗
44. 10.1021/acs.chemrev.8b0062610.1021/acs.chemrev.8b00626 ↗
45. 10.1002/advs.20200279710.1002/advs.202002797 ↗
46. 10.1039/D2BM01833K10.1039/D2BM01833K ↗
47. 10.1038/s41581-022-00631-710.1038/s41581-022-00631-7 ↗
48. 10.7150/thno.4541310.7150/thno.45413 ↗